Eloralintide Phase 2: 263 adults, 48 weeks, mean weight reductions of 9.5%-20.1% versus 0.4% for placebo, with about 20.1% at the 9 mg dose
Weight gain during active tirzepatide treatment is rare but possible if doses are missed frequently, food portions exceed appetite suppression capacity, or underlying metabolic conditions interfere with the medication's effect
For clients who are putting in the work and want metabolic support, this is a clinically grounded addition to their protocol
Cellular Senescence Research: the compound is studied in longevity and cellular senescence models where NAD+ decline is a characterized feature
Wegovy is used for weight management in adults who are overweight or obese with at least one related condition including type 2 diabetes, high cholesterol, or high blood pressure
Lets walk through the most common places to find a provider